This Week in Gastroenterology — Jul 31, 2026

Welcome to This Week in Gastroenterology. This week we're covering 9 notable papers spanning advances in metabolic liver disease and portal hypertension, endoscopic innovations in esophageal disorders, and evolving paradigms in diagnostic criteria, screening, and clinical trial design. Let's dive in.\n\nWe begin with metabolic dysfunction-associated steatotic liver disease, or MASLD, and its progression to advanced liver disease. In a post hoc analysis of the phase 3 MAESTRO-NASH trial published in Alimentary Pharmacology & Therapeutics, researchers evaluated the efficacy of resmetirom specifically in the 917 patients with moderate-to-advanced, stage F2 and F3 fibrosis, which aligns with the drug's approved label [1]. Over 52 weeks, once-daily oral resmetirom at 80 milligrams or 100 milligrams achieved metabolic dysfunction-associated steatohepatitis resolution in roughly 26% and 30% of patients respectively, compared to just under 10% in the placebo group. Fibrosis improvement of at least one stage without worsening of activity scores was also achieved by about 27% of patients on the 80-milligram dose and 29% on the 100-milligram dose, compared to roughly 17% on placebo. Low-density lipoprotein cholesterol fell by about 12% to 14% with the active drug but rose slightly with placebo, confirming that the efficacy and safety of resmetirom in the specific label-approved F2 to F3 population mirror the primary trial results. Moving from clinical trial data to large-scale population science, a study in Gut applied latent class analysis to over 48,000 United Kingdom Biobank participants with magnetic resonance imaging-based proton density fat fraction data to map the molecular heterogeneity of MASLD [8]. The researchers identified distinct clinical subtypes and a striking sexual dimorphism in disease severity. By analyzing large-scale proteomics, they developed a four-protein score, known as the PS4, which includes proteins linked to hepatic lipid and one-carbon metabolism, as well as immune and vascular integrity. In a validation cohort of over 115,000 participants, this four-protein score significantly outperformed established non-invasive liver-centric scores in predicting all-cause mortality, showing that MASLD-driven proteomic shifts reflect systemic biological pathways that link hepatic metabolic dysfunction directly with long-term survival.\n\n For patients whose chronic liver diseases progress to cirrhosis, muscle wasting is a critical concern that directly impacts survival. A cohort study in Gut characterized the natural history of skeletal muscle loss in 364 ambulatory adults with cirrhosis awaiting liver transplantation [3]. Over a median follow-up, patients lost a median of 1.6% of their skeletal muscle index per year. However, the one-quarter of patients with the fastest decline, termed rapid muscle loss, lost more than 7.4% of their muscle mass annually. Independent predictors of this rapid loss were the presence of ascites, which nearly doubled the risk, and a higher model for end-stage liver disease-sodium, or MELD-Na, score. Crucially, rapid muscle loss was a powerful independent predictor of waitlist mortality, with 12-month mortality rates more than tripling to 32% compared to 10% in those without rapid loss. While sarcopenia represents a physical decline, decompensated cirrhosis is also accompanied by a profound immunological decline known as cirrhosis-associated immune dysfunction, which leaves patients highly vulnerable to bacterial infections. A prospective cohort study published in Gut investigated whether portal hypertension is the primary driver of this immune dysfunction and whether reducing portal pressure via a transjugular intrahepatic portosystemic shunt, or TIPS, could reverse it [5]. Analyzing 75 patients undergoing TIPS, researchers found that markers of gut barrier breakdown, bacterial translocation, systemic inflammation, and monocyte activation were elevated at baseline but significantly decreased after TIPS. In vitro, sera from patients before TIPS induced an anti-inflammatory, immunosuppressed signature in healthy monocytes, which resolved after TIPS. This immunological recovery occurred only in patients who achieved resolution of their ascites and was associated with a reduction in actual bacterial infections, demonstrating that portal decompression directly restores gut barrier integrity and re-establishes immune homeostasis.\n\n Next, we turn to the upper gastrointestinal tract, where endoscopic techniques continue to redefine the management of motility and anatomical disorders. In Gastrointestinal Endoscopy, a retrospective cohort study evaluated the long-term safety and efficacy of peroral endoscopic myotomy, or POEM, in 30 children with achalasia, with a median follow-up of 36 months [7]. Clinical success, defined as an Eckardt score of 3 or less, was achieved in over 93% of the pediatric patients, accompanied by significant reductions in timed barium esophagram measurements, improvements in body mass index z-scores, and zero major adverse events. This provides reassuring evidence that the clinical benefits of POEM in children are durable up to three years. Meanwhile, for Zenker's diverticulum, clinicians are increasingly choosing between flexible endoscopic septotomy, or FES, and Zenker's peroral endoscopic myotomy, known as Z-POEM. A cost-effectiveness analysis in Gastrointestinal Endoscopy compared these two approaches over 12-month and 24-month horizons [6]. At 12 months, because of higher procedural costs, Z-POEM was not cost-effective, yielding an incremental cost-effectiveness ratio of over 390,000 dollars per quality-adjusted life year, which is well above standard willingness-to-pay thresholds. However, when the model was extended to 24 months to account for long-term recurrences, Z-POEM became the cost-effective choice. This shift was driven by its superior durability and a reduced need for repeat interventions, suggesting that while flexible endoscopic septotomy is the economically preferred short-term strategy, Z-POEM offers better long-term economic and clinical value.\n\n Finally, we look at papers shaping how we define, screen, and design clinical trials for common gastrointestinal conditions. The transition from the Rome IV to the Rome V diagnostic criteria for irritable bowel syndrome, or IBS, has introduced significant changes, primarily by altering symptom frequency and persistence requirements and excluding patients with continuous abdominal pain. A study in Clinical Gastroenterology and Hepatology compared these criteria in a survey of over 1,200 United Kingdom adults with self-reported IBS [2]. While 59% of respondents met the Rome IV criteria, 70% met the Rome V criteria. The agreement between the two was only fair. Notably, patients classified under Rome V reported lower symptom severity, less psychological comorbidity, higher quality of life, and less impairment in work and social activities than those meeting Rome IV. Furthermore, Rome V IBS was less stable over longitudinal follow-up. This indicates that Rome V captures a clinically milder and less stable cohort, which clinicians and researchers must keep in mind when interpreting future trial data and managing patients. In the realm of colorectal cancer screening, non-invasive stool tests are highly effective, but their success hinges on timely follow-up colonoscopies for positive results. A review article in Gastrointestinal Endoscopy highlights that follow-up rates remain suboptimal and outlines evidence-based interventions to close this gap [4]. Key recommendations for health systems and endoscopists include implementing dedicated patient navigation programs, utilizing digital communication tools, and establishing open-access colonoscopy pathways. Lastly, drug development for celiac disease faces unique hurdles, as a strict gluten-free diet is currently the only management option but is often incomplete and highly burdensome. A review in Alimentary Pharmacology & Therapeutics summarizes a multi-stakeholder meeting involving the United States Food and Drug Administration, academics, and industry representatives [9]. The panel emphasized that regulatory approval for new therapies will require evidence of both symptom relief and histological healing as co-primary endpoints, particularly in patients with active baseline disease. The report outlines practical strategies for standardizing biopsy acquisition, defining meaningful histological change, and using controlled gluten exposure safely in trials to accelerate the development of much-needed adjunctive therapies.\n\n If you only have time for one paper this week, make it the post hoc analysis of the phase 3 MAESTRO-NASH trial evaluating resmetirom in patients with stage F2 and F3 fibrosis [1]. This study is highly practice-changing because it confirms the efficacy and safety of the first approved drug for metabolic dysfunction-associated steatohepatitis specifically in the moderate-to-advanced fibrosis population that matches the drug's FDA-approved label.\n\n Here are the key takeaways from this week in Gastroenterology. First, resmetirom is effective and safe for patients with MASH and stage F2 or F3 fibrosis, achieving significant rates of disease resolution and fibrosis improvement over 52 weeks. Second, rapid skeletal muscle loss of more than 7.4% per year occurs in one-quarter of ambulatory patients with cirrhosis and is a powerful independent predictor of waitlist mortality, particularly in those with ascites or higher MELD-Na scores. Third, the new Rome V criteria for irritable bowel syndrome identify a clinically milder and less stable cohort than Rome IV, primarily due to the exclusion of patients with continuous pain. Fourth, while flexible endoscopic septotomy is the more cost-effective option for Zenker's diverticulum over a 12-month period, Z-POEM becomes cost-effective by 24 months due to superior durability and fewer recurrences. And fifth, reducing portal hypertension with TIPS significantly reverses markers of gut barrier dysfunction and systemic inflammation, helping to restore immune homeostasis in patients who achieve ascites resolution.\n\nThat's your roundup for This Week in Gastroenterology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And if you have a paper you have been meaning to read, upload the PDF, or paste any link, at audioscholar dot C C. We will turn it into audio like this one, in any of thirty-one languages.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.